PeptideStack
5.2kquestions
20kanswers
220users

Why would Medutest report 98.4% where the supplier certificate says something higher?

Asked 17 May 2025Modified 11 months agoViewed 13k times
This question was marked as a duplicate of Why would Medutest report 96.8% where the supplier certificate says something higher?Closed 1 Jun 2025. It remains here because the answers below are specific to how it was asked.
34

Details up front: Medutest · 98.4%.

Before I write this off, I want to check whether it is a known failure mode.

I have the lot number, the certificate and the date, and I am happy to compare them against anything.

What is the differential here, and which test discriminates between the options?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questions
medutest
medutest

Medutest, one of four independent testing and verification services referenced throughout this site. Use this tag for its methods, its report…

126 questions
shareeditfollowflag
JE
askedjonas_ekstrom12k3817 May 2025
3Voting to keep this open — it is more specific than it first looks. – cold_lane 6 months ago
add a comment

5 Answers

Sorted by votes
8

A 98.4 per cent result against a higher certificate figure is usually a method difference, not a disagreement about the vial. Inter-laboratory spread on identical peptide material runs half a per cent to a full per cent by RP-HPLC. Gradient slope, detection wavelength and integration convention each move the number, and a gentler gradient resolves impurities that a steeper one hides under the main peak — so the better method reports the worse figure. Get the column, the gradient and the wavelength from both Medutest and the supplier before treating 98.4 per cent as a contradiction.

Start from what the detector sees, because that tells you what the number means.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

The part that matters: column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
LD
answeredloss_on_drying40k13827 Jul 2025
3This should be linked from the help pages. – RP_C18 3 months ago
4I would gently push back on the second point — inter-laboratory spread is wider than stated. – meniscus_film 4 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
7

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Specifically, buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
TM
answeredtobias_maartens171k35830 Aug 2025
6

Worth being precise here: purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Stated carefully, tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
RC
answeredRP_C18105k34819 Aug 2025
Thank you — this is the answer I was looking for. – coldpack_88 7 months ago
Adding for future readers: the certificate should carry the lot number, not just a batch code. – klara_novotna 9 months ago
add a comment
1

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
M4
answeredmz_4113101k35824 May 2025
-1

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
SC
answeredstopper_core28k1277 Aug 2025
3The system-suitability data is the part that tells you whether to believe the rest. – ines_brandt 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.